{"id":5312,"date":"2026-07-18T07:00:50","date_gmt":"2026-07-18T07:00:50","guid":{"rendered":"https:\/\/echeloncreativemedia.com\/marketvows\/2026\/07\/18\/wall-street-eyes-pet-obesity-glp-1-weight-loss-drugs-headed-for-overweight-cats-reshaping-a-200b-industry\/"},"modified":"2026-07-18T07:00:50","modified_gmt":"2026-07-18T07:00:50","slug":"wall-street-eyes-pet-obesity-glp-1-weight-loss-drugs-headed-for-overweight-cats-reshaping-a-200b-industry","status":"publish","type":"post","link":"https:\/\/echeloncreativemedia.com\/marketvows\/2026\/07\/18\/wall-street-eyes-pet-obesity-glp-1-weight-loss-drugs-headed-for-overweight-cats-reshaping-a-200b-industry\/","title":{"rendered":"Wall Street Eyes Pet Obesity: GLP-1 Weight-Loss Drugs Headed for Overweight Cats, Reshaping a $200B Industry"},"content":{"rendered":"

The booming GLP-1 weight-loss drug market is extending its reach into veterinary medicine, with biotech companies like Akston Biosciences and OKAVA Pharmaceuticals developing treatments for overweight cats. This marks a significant shift from premium pet food to medicalization within the $200 billion U.S. pet economy, drawing attention from major players like Nestl\u00e9 and animal-health firms such as Zoetis. While affordability remains a key factor for pet owners, the trend points to a future where therapeutics, advanced nutrition, and longevity solutions converge in pet care.<\/p>\n

<\/p>\n

READ MORE FROM CNBC<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

The booming GLP-1 weight-loss drug market is extending its reach into veterinary medicine, with biotech companies like Akston Biosciences and OKAVA Pharmaceuticals developing treatments for overweight cats. This marks a significant shift from premium pet food to medicalization within the $200 billion U.S. pet economy, drawing attention from major players like Nestl\u00e9 and animal-health firms […]<\/p>\n","protected":false},"author":1,"featured_media":5313,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/image.cnbcfm.com\/api\/v1\/image\/108335808.jpg","fifu_image_alt":"","footnotes":""},"categories":[28,31],"tags":[],"class_list":["post-5312","post","type-post","status-publish","format-standard","has-post-thumbnail","category-economy","category-technology","rifnote_country-u-s","rifnote_executive-todd-zion"],"fifu_image_url":"https:\/\/image.cnbcfm.com\/api\/v1\/image\/108335808.jpg","_links":{"self":[{"href":"https:\/\/echeloncreativemedia.com\/marketvows\/wp-json\/wp\/v2\/posts\/5312","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/echeloncreativemedia.com\/marketvows\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/echeloncreativemedia.com\/marketvows\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/echeloncreativemedia.com\/marketvows\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/echeloncreativemedia.com\/marketvows\/wp-json\/wp\/v2\/comments?post=5312"}],"version-history":[{"count":0,"href":"https:\/\/echeloncreativemedia.com\/marketvows\/wp-json\/wp\/v2\/posts\/5312\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/echeloncreativemedia.com\/marketvows\/wp-json\/wp\/v2\/media\/5313"}],"wp:attachment":[{"href":"https:\/\/echeloncreativemedia.com\/marketvows\/wp-json\/wp\/v2\/media?parent=5312"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/echeloncreativemedia.com\/marketvows\/wp-json\/wp\/v2\/categories?post=5312"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/echeloncreativemedia.com\/marketvows\/wp-json\/wp\/v2\/tags?post=5312"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}